PROSTATE BIOPSIES in men with a PSA level of 4.01-10.0 ng/mL and normal findings on digital rectal examination (DRE) should include lateral cores in addition to the sextant biopsy, according to investigators.

SAN FRANCISCO—A PSA velocity (PSAV) threshold of 0.4 ng/mL per year can distinguish between clinically significant and insignificant prostate cancer, new data suggest.

Following an initial PSA test result of 3.0-19.99 ng/mL in men aged 50-70 years, a repeat PSA test within seven weeks allows for more accurate assessment as to whether a biopsy will reveal prostate cancer, a British team reports.

LONG-TERM antibiotic therapy for men with biopsy-proven asymptomatic prostatitis may not significantly alter elevated PSA levels, data show.

GRAY-SCALE transrectal ultrasonography (TRUS) alone has a limited potential to detect prostate cancer, particularly in patients with total PSA levels below 20 ng/mL, researchers reported in the Journal of Medical Imaging and Radiation Oncology (2008;52:24-28).

DELAYED CLINICIAN response to a patient's abnormal PSA level occurs in about 23% of cases, which may be more common than generally appreciated, according to researchers.

Grey-scale transrectal ultrasonography (TRUS) alone has a limited potential to detect prostate cancer, particularly in patients with total PSA levels below 20 ng/mL, researchers reported in the Journal of Medical Imaging and Radiation Oncology (2008;52:24-28).

HEMODILUTION from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers.

Using an assay they developed to detect antibodies to Propionibacterium acnes bacteria, researchers have found a link between these bacteria and development of inflammation-related prostate diseases.

Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers.